ALK and non-small cell lung carcinoma: Thus, the objective of this large, retrospective, real-world study is to describe sequencing patterns and treatment effectiveness of 1L and 2L treatments in patients with ALK-positive advanced NSCLC who initiated 1L alectinib or brigatinib treatment in routine clinical practice in the United States (US).